DEVELOPMENT OF A QUALIFICATION PROCEDURE FOR METHIONINE FORM OF INTERFERON ALFA-2b STANDARD TO CONFIRM ITS AUTHENTICITY BY MEANS OF A PEPTIDE MAPPING METHOD

DEVELOPMENT OF A QUALIFICATION PROCEDURE FOR METHIONINE FORM OF INTERFERON ALFA-2b STANDARD TO CONFIRM ITS AUTHENTICITY BY MEANS OF A PEPTIDE MAPPING METHOD

Authenticity evaluation of proteins obtained with recombinant DNA technology is an important step in confirming efficacy and safety of the drugs based on them. One of the main ways to assess the authenticity is to compare molecular structure of the test and standard samples using the peptide mapping...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. B. Ustinnikova, E. O. Goloshchapova, O. B. Runova, M. G. Korotkov, R. A. Volkova
Format:	Article
Language:	Russian
Published:	St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2018-06-01
Series:	Медицинская иммунология
Subjects:	substance interferon alfa-2b authenticity peptide mapping standard sample
Online Access:	https://www.mimmun.ru/mimmun/article/view/1562
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Complex treatment of allergic eye diseases using interferon alfa-2b and loratadine gel for topical and external use
by: A. V. Surov,, et al.
Published: (2014-07-01)

The effectiveness of the use of the drug recombinant interferon alfa-2b for the prevention of acute respiratory infections in preschool children
by: S. A. Drakina, et al.
Published: (2019-12-01)

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01)

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01)

Еxternal forms of recombinant interferon alfa-2b - ointment and gel in the treatment of acute respiratory viral infections and influenza in children
by: O. V. Shamsheva, et al.
Published: (2020-06-01)

CLINICAL AND IMMUNOLOGICAL EFFICACY OF THE RECOMBINANT INTERFERON alfa-2b OF ACUTE EPSTEIN-BARR VIRAL MONONUCLEOSIS IN PRESCHOOL CHILDREN
by: V. N. Timchenko, et al.
Published: (2016-09-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
by: Leslie Pérez Ruiz, et al.
Published: (2007-12-01)

Investigation into the pharmacodynamics and pharmacokinetics of recombinant human interferon alfa-2b vaginal suppository following process optimization in chinese rhesus macaque
by: Xueyan Zhang, et al.
Published: (2025-05-01)

Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon
by: Patrícia Alessandra Dastoli, et al.
Published: (2011-02-01)

The efficiency of interferon therapy for acute respiratory viral infections in young children
by: T. K. Chudakova, et al.
Published: (2020-03-01)

Treatment of chronic hepatitis C among injecting drug users: A 5-year follow-up
by: Ruzić Maja, et al.
Published: (2013-01-01)

CLINICAL AND LABORATORY CHARACTERISTICS OF CHRONIC HEPATITIS C IN VIETNAM ON THE EXAMPLE OF HO CHI MINH CITY HEPATOLOGY CLINIC
by: D. A. Lioznov, et al.
Published: (2016-12-01)

EFFECTIVENESS AND SAFETY OF VELAGLUCERASE ALFA IN TREATMENT OF GAUCHER DISEASE TYPE 1 (ACCORDING TO INTERNATIONAL STUDIES)
by: O. S. Gundobina, et al.
Published: (2014-11-01)

PET imaging of differentiated thyroid cancer with thyrotropin-alfa
by: Grayson R. Gimblet, et al.
Published: (2025-04-01)

Successful desensitization protocol to alglucosidase and avalglucosidase alfa in a patient with infantile-onset Pompe disease
by: Miriam Gendive, et al.
Published: (2025-06-01)

Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy
by: Ružić Maja, et al.
Published: (2018-01-01)

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy
by: Uma Ramaswami, et al.
Published: (2025-06-01)

Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies
by: K. A. Perova, et al.
Published: (2022-04-01)

Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies
by: Fatma Al Jasmi, et al.
Published: (2025-03-01)

Interferon Status and Choice of Interferons Inducers in Frequently Ill Children
by: M. S. Savenkovа, et al.
Published: (2016-06-01)

LOCAL APPLICATION OF RECOMBINANT INTERFERON-ALFA2 FOR TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
by: M. Plouzhnikov, et al.
Published: (2014-07-01)

Effects of asfotase alfa on fracture healing of adult patient with hypophosphatasia and literature review
by: Songqi Wang, et al.
Published: (2025-04-01)

Combined Use of Bevacizumab + Interferon A-2 α in the Treatement of Patients with Disseminated Kidney Cancer in Comparison with an Active Monitoring Group
by: K. Sh. Gantsev, et al.
Published: (2019-03-01)

Aspects of a Methodological Approach to Determination of Interferon Alpha Specific Activity
by: M. L. Baykova, et al.
Published: (2020-03-01)

The expression of interferon-stimulated genes (interferon “signature”) in patients with rheumatoid arthritis (Preliminary results)
by: A. S. Avdeeva, et al.
Published: (2021-01-01)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01)

Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022
by: D. G. Shchurov, et al.
Published: (2023-04-01)

Organizing pneumonia in a patient following treatment of chronic hepatitis B with pegylated interferon alfa-2b: A case report
by: Bing Tian, et al.
Published: (2025-01-01)

The use in pediatrics of recombinant interferon alfa-2b preparations in the dosage form rectal suppositories: whom? when? which ones?
by: M. S. Savenkova, et al.
Published: (2021-04-01)

Prevention of COVID-19 in family foci
by: A. V. Mordyk, et al.
Published: (2021-06-01)

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice
by: N. P. Blokhina, et al.
Published: (2016-07-01)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018-11-01)

Use of dornase alfa in the management of life-threatening mucostasis in airway stents: its efficacy and safety
by: Demet Turan, et al.
Published: (2025-02-01)

Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)
by: Ilaria Ammendolia, et al.
Published: (2024-11-01)

ADMINISTRATION CRITERIA FOR INTERFERON-BASED DRUGS AND ITS INDUCERS IN ACUTE RESPIRATORY INFECTIONS IN CHILDREN
by: E. G. Golovacheva, et al.
Published: (2014-07-01)

Innovative passwordless authentication approaches in IoT identity management
by: Venkatrao A. Kommuri, et al.
Published: (2025-06-01)

Single-chain recombinant clotting factor VIII (lonoctocog alfa): clinical experience in Russia
by: M. V. Kosinova
Published: (2022-02-01)

Alfa-mannosidosis: Frequent Symptoms in Rare Patient
by: Nato D. Vashakmadze, et al.
Published: (2023-01-01)

Generation of the MCF-7 cell sublines with CRISPR/Cas9 mediated disruption of estrogen receptor alfa (ESR1) expression
by: L. O. Savinska, et al.
Published: (2024-12-01)